A look at pharma’s many TV spokes-creatures

Damian Garde Over the past decade, pharma companies have increasingly relied on animated characters to advertise their products, using cute, quaint or questionable creatures to illustrate ...

Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Carly Helfand Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance. FiercePharma News

Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round

John Carroll Adicet Bio has jumped out of stealth mode–more or less–with a $ 51 million A round and plans to combine two platform technologies into a next-gen approach ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

Facing extinction, MannKind is reportedly looking to sell itself

Damian Garde Struggling drugmaker MannKind is looking for a way out of its perilous financial situation, according to Reuters, scouting for a buyer in the wake of ex-partner Sanofi's ...

Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Novartis reshuffles its $9B R&D operation to save $1B a year

Damian Garde Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines. FierceBiotech News

Gilead faces legal action in Massachusetts if it doesn’t cut hep C prices: State AG

Tracy Staton Gilead Sciences is facing more hepatitis C pushback from state officials. The Massachusetts attorney general is warning that it will take legal action against the California-based ...

Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings

Emily Wasserman Big Pharma can celebrate a bright point. Arizona's top court ruled that drugmakers don't have an obligation to warn patients directly about safety risks of their ...

Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently ...

Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day

Nick Paul Taylor Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round ...

J&J’s new launches deliver, but overall sales fall short on hep C, strong dollar

Carly Helfand Johnson & Johnson's hep C sales have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a strong dollar ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS